Pacira BioSciences, Inc. (PCRX): Price and Financial Metrics

PCRX POWR Grades

• PCRX scores best on the Growth dimension, with a Growth rank ahead of 96.89% of US stocks.
• The strongest trend for PCRX is in Growth, which has been heading up over the past 179 days.
• PCRX ranks lowest in Momentum; there it ranks in the 8th percentile.

PCRX Stock Summary

• PCRX's current price/earnings ratio is 81.38, which is higher than 91.31% of US stocks with positive earnings.
• With a year-over-year growth in debt of 108.61%, Pacira BioSciences Inc's debt growth rate surpasses 90.46% of about US stocks.
• In terms of twelve month growth in earnings before interest and taxes, Pacira BioSciences Inc is reporting a growth rate of 92.64%; that's higher than 79.07% of US stocks.
• Stocks that are quantitatively similar to PCRX, based on their financial statements, market capitalization, and price volatility, are ICHR, INPX, XL, ONTF, and RGEN.
• PCRX's SEC filings can be seen here. And to visit Pacira BioSciences Inc's official web site, go to www.pacira.com.

PCRX Valuation Summary

• In comparison to the median Healthcare stock, PCRX's price/earnings ratio is 58.63% lower, now standing at 15.1.
• Over the past 129 months, PCRX's price/sales ratio has gone down 2.9.
• Over the past 129 months, PCRX's EV/EBIT ratio has gone up 41.4.

Below are key valuation metrics over time for PCRX.

PCRX Growth Metrics

The 4 year price growth rate now stands at -16.16%.
• Its 4 year net income to common stockholders growth rate is now at 97.36%.
• Its 5 year cash and equivalents growth rate is now at 55.84%.

Over the past 34 months, PCRX's revenue has gone up $187,551,000.

The table below shows PCRX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	541.533	125.717	41.98
2021-09-30	513.313	149.169	61.625
2021-06-30	503.075	128.663	174.084
2021-03-31	442.99	82.905	147.734
2020-12-31	429.647	77.032	145.523
2020-09-30	421.097	56.269	126.121

PCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• PCRX has a Quality Grade of C, ranking ahead of 72.8% of graded US stocks.
• PCRX's asset turnover comes in at 0.394 -- ranking 116th of 681 Pharmaceutical Products stocks.
• BCDA, NVAX, and RDHL are the stocks whose asset turnover ratios are most correlated with PCRX.

The table below shows PCRX's key quality metrics over time.